{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:29:33Z","timestamp":1792099773847,"version":"4.4.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.amjcard.2025.10.013","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T15:16:05Z","timestamp":1761146165000},"page":"287-301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Heart Failure With Preserved Ejection Fraction and Chronic Kidney Disease: From Pathophysiology to Treatment"],"prefix":"10.1016","volume":"258","author":[{"given":"Rita Micaelo","family":"Grilo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3574-9807","authenticated-orcid":false,"given":"L. Menezes","family":"Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2025.10.013_bib0001","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0002","doi-asserted-by":"crossref","first-page":"E139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics\u20142020 update a report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0003","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ejhf.445","article-title":"Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction","volume":"18","author":"Unger","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0004","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/00015385.2020.1770460","article-title":"Pouleur A-C. Heart failure with preserved ejection fraction in Belgium: characteristics and outcome of a real-life cohort","volume":"76","author":"Lejeune","year":"2021","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0005","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ejhf.821","article-title":"Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"19","author":"L\u00f6fman","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100624","article-title":"All-cause and cardiovascular-related mortality in CKD patients with and without heart failure: a population-based cohort study in Kaiser Permanente Southern CA","volume":"5","author":"Yu","year":"2023","journal-title":"Kidney Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0007","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11897-023-00615-z","article-title":"Discovering distinct phenotypical clusters in heart failure across the ejection fraction spectrum: a systematic review","volume":"20","author":"Meijs","year":"2023","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0008","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11897-023-00598-x","article-title":"Sex differences in cardiorenal syndrome: insights from CARDIOREN Registry","volume":"20","author":"M","year":"2023","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0009","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/eurheartj\/ehp507","article-title":"Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative","volume":"31","author":"Ronco","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0010","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal Syndrome revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0011","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ejhf.497","article-title":"Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation","volume":"18","author":"ter","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0012","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.12.045","article-title":"Inflammatory markers and incident heart failure risk in older adults","volume":"55","author":"Kalogeropoulos","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0013","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.111.076075","article-title":"Low myocardial protein kinase G activity in heart failure with preserved ejection fraction","volume":"126","author":"van","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100723","article-title":"Fibroblast growth factor 23 and risk of heart failure subtype: the CRIC (Chronic Renal Insufficiency Cohort) study","volume":"5","author":"Leidner","year":"2023","journal-title":"Kidney Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijcard.2019.08.040","article-title":"Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction","volume":"296","author":"Vergaro","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0016","first-page":"1","article-title":"Clinical implications of mineralocorticoid receptor overactivation","volume":"18","author":"El","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117332","article-title":"A systematic review concerning the relation between the sympathetic nervous system and heart failure with preserved left ventricular ejection fraction","volume":"10","author":"Verloop","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0018","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.hfc.2014.03.001","article-title":"Invasive hemodynamic characterization of heart failure with preserved ejection fraction","volume":"10","author":"Andersen","year":"2014","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0019","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/HJH.0000000000003069","article-title":"Prevalence and renal prognosis of left ventricular diastolic dysfunction in non-dialysis chronic kidney disease patients with preserved systolic function","volume":"40","author":"Borrelli","year":"2022","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0020","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1093\/eurheartj\/ehu193","article-title":"Right heart dysfunction in heart failure with preserved ejection fraction","volume":"35","author":"Melenovsky","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0021","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ehf2.13118","article-title":"Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives","volume":"8","author":"Husain-Syed","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0022","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jacc.2008.08.080","article-title":"Increased Central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease","volume":"53","author":"Damman","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0023","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1093\/eurheartj\/ehy268","article-title":"Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction","volume":"39","author":"Obokata","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0024","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.amjcard.2015.06.038","article-title":"Association of chronic kidney disease with chronotropic incompetence in heart failure with preserved ejection fraction","volume":"116","author":"Klein","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0025","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2019-001012","article-title":"Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"6","author":"Beale","year":"2019","journal-title":"Open Heart"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0026","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2215\/CJN.15360920","article-title":"Heart failure hospitalization risk associated with iron status in veterans with CKD","volume":"16","author":"Cho","year":"2021","journal-title":"Clin J Am Society Nephrol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0027","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3390\/jcm11010125","article-title":"Iron Deficiency in heart failure: mechanisms and pathophysiology","volume":"11","author":"Alnuwaysir","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0028","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/eurheartj\/ehad131","article-title":"Iron deficiency in heart failure across the spectrum of left ventricular ejection fraction: dotting the i\u2019s","volume":"44","author":"Verelst","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0029","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1016\/j.ekir.2021.07.032","article-title":"Iron deficiency in CKD without concomitant anemia","volume":"6","author":"Wish","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0030","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction","volume":"83","author":"Maddox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0031","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","article-title":"Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial","volume":"45","author":"von","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0032","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/ndt\/gfw264","article-title":"Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial","volume":"32","author":"Roger","year":"2017","journal-title":"Nephrol Dialys Transplantat"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0033","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0034","article-title":"Chronic kidney disease as a risk factor for heart failure with preserved ejection fraction: a focus on microcirculatory factors and therapeutic targets","volume":"10","author":"de","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0036","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1681\/ASN.2020071041","article-title":"The mineralocorticoid receptor in salt-sensitive hypertension and renal injury","volume":"32","author":"Ayuzawa","year":"2021","journal-title":"J Am Society Nephrol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0037","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/ajh\/hpy120","article-title":"Mineralocorticoid receptor and cardiovascular disease","volume":"31","author":"Buonafine","year":"2018","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0038","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11897-024-00691-9","article-title":"Atrial fibrillation in heart failure: novel insights, challenges, and treatment opportunities","volume":"22","author":"Bidaoui","year":"2025","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0039","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jacc.2020.07.009","article-title":"Atrial dysfunction in patients with heart failure with preserved ejection fraction and Atrial fibrillation","volume":"76","author":"Reddy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0040","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.yjmcc.2025.06.002","article-title":"Mechanisms underlying atrial fibrillation in chronic kidney disease","volume":"205","author":"Navarro-Garcia","year":"2025","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.119055","article-title":"Interaction between chronic kidney disease and atrial fibrillation on incident stroke and all-cause mortality: matched cohort study of 49,594 patients","volume":"401","author":"Chang","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0042","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijcard.2020.08.003","article-title":"Kidney function and the risk of heart failure in patients with new-onset atrial fibrillation","volume":"320","author":"Carrero","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0043","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jacc.2025.03.429","article-title":"Finerenone reduces new-onset atrial fibrillation across the spectrum of cardio-kidney-metabolic syndrome","volume":"85","author":"Pabon","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0044","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1161\/STR.0000000000000476","article-title":"Cardiac Contributions to Brain health: a scientific statement from the American Heart Association","volume":"55","author":"Testai","year":"2024","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0045","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/ndt\/gfae079","article-title":"Impaired kidney function, cerebral small vessel disease and cognitive disorders: the Framingham Heart Study","volume":"39","author":"Kelly","year":"2024","journal-title":"Nephrol Dialysis Transplantat"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0046","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","article-title":"Heart failure in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"95","author":"House","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0047","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/ndt\/gfad011","article-title":"Management of heart failure in patients with kidney disease\u2014Updates from the 2021 ESC guidelines","volume":"38","author":"Edwards","year":"2023","journal-title":"Nephrol Dialysis Transplantat"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0048","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jchf.2024.04.030","article-title":"Prevalence and implications of heart failure stages A-D among patients with chronic kidney disease","volume":"12","author":"Lauridsen","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0049","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40292-024-00631-7","article-title":"Clinical implications of estimating glomerular filtration rate with different equations in heart failure patients with preserved ejection fraction","volume":"31","author":"Zhang","year":"2024","journal-title":"High Blood Pressure Cardiovasc Prevent"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0051","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.cardfail.2022.03.203","article-title":"Cystatin C predicts adverse outcomes In heart failure with preserved ejection fraction","volume":"28","author":"Burns","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0052","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jacc.2025.03.009","article-title":"Interplay of chronic kidney disease and the effects of tirzepatide in patients with heart failure, preserved ejection fraction, and obesity","volume":"85","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0053","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.peptides.2018.04.003","article-title":"Renal function, N-terminal Pro-B-type natriuretic peptide, propeptide big-endothelin and patients with heart failure and preserved ejection fraction","volume":"111","author":"Gergei","year":"2019","journal-title":"Peptides (NY)"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0054","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae199","article-title":"CA125 outperforms NT-proBNP in the prediction of maximum aerobic capacity in heart failure with preserved ejection fraction and kidney dysfunction","volume":"17","author":"N\u00fa\u00f1ez-Mar\u00edn","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0055","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.940641","article-title":"The diagnostic accuracy of N-terminal pro-B-type natriuretic peptide and soluble ST2 for heart failure in chronic kidney disease patients: a comparative analysis","volume":"29","author":"Ma","year":"2023","journal-title":"Med Sci Monitor"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0056","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s00392-024-02382-w","article-title":"Circulating osteoprotegerin as a cardiac biomarker for left ventricular diastolic dysfunction in patients with pre-dialysis chronic kidney disease: the KNOW-CKD study","volume":"113","author":"Suh","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0057","first-page":"e263","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0058","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","article-title":"Trial of intensive blood-pressure control in older patients with hypertension","volume":"385","author":"Zhang","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0059","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0060","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/jamacardio.2023.1090","article-title":"Safety and efficacy of empagliflozin and diuretic use in patients with heart failure and preserved ejection fraction","volume":"8","author":"Butler","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0061","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jchf.2023.06.036","article-title":"Efficacy and safety of Empagliflozin according to background diuretic use in HFrEF","volume":"12","author":"Dhingra","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0062","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in Heart Failure","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0063","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1093\/eurheartj\/ehad557","article-title":"Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial","volume":"44","author":"Meekers","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0064","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s10157-022-02224-x","article-title":"Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial","volume":"26","author":"Komiya","year":"2022","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0065","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/clc.23392","article-title":"Hyperkalemia in heart failure: foe or friend?","volume":"43","author":"Rakisheva","year":"2020","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0066","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jchf.2018.10.003","article-title":"Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"7","author":"Savarese","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0067","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cardfail.2018.03.002","article-title":"Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial","volume":"24","author":"Desai","year":"2018","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0068","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"E.mpagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0069","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0070","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0071","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0072","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s10741-023-10324-3","article-title":"Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an overview of 36 systematic reviews","volume":"28","author":"Karakasis","year":"2023","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0073","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0074","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0075","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0076","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0077","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0078","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0079","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.amjcard.2021.01.018","article-title":"Effect of obesity on response to spironolactone in patients with heart failure with preserved ejection fraction","volume":"146","author":"Elkholey","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0081","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/ejhf.2469","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the <scp>FIDELIO-DKD<\/scp>trial","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0082","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0083","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0084","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with Empagliflozin in chronic kidney disease and type 2 diabetes","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0085","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/ejhf.3294","article-title":"Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b <scp>MIRACLE<\/scp>trial","volume":"26","author":"Lam","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0087","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0088","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction","volume":"142","author":"FR","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0089","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jchf.2024.08.022","article-title":"Angiotensin receptor neprilysin inhibition and cardiovascular outcomes across the kidney function spectrum","volume":"13","author":"Mc Causland","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0090","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029565","article-title":"Updates for cardio-kidney protective effects by angiotensin receptor-neprilysin inhibitor: requirement for additional evidence of kidney protection","volume":"12","author":"Tsukamoto","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0091","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of Sacubitril\/Valsartan versus Irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0092","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0093","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","article-title":"Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF","volume":"44","author":"Vaduganathan","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0094","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3390\/jcm13061572","article-title":"The efficacy and safety of Sacubitril\/Valsartan compared to Valsartan in patients with heart failure and mildly reduced and preserved ejection fractions: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Kommu","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0095","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0096","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"The Lancet"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0097","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0098","article-title":"Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction","author":"Martin","year":"2021","journal-title":"Cochr Database Systemat Rev"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0099","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ehf2.12204","article-title":"Renin\u2013angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"4","author":"Khan","year":"2017","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0100","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jacc.2014.01.087","article-title":"Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment","volume":"64","author":"Damman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0101","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/ejhf.609","article-title":"Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the <scp>CHARM<\/scp>-study programme","volume":"18","author":"Damman","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0102","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s11255-021-03025-z","article-title":"Efficacy of medication therapy for patients with chronic kidney disease and heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"54","author":"Yang","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0103","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/2047487318780035","article-title":"Efficacy of renin\u2013angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease","volume":"25","author":"Tsujimoto","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0104","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4070\/kcj.2023.0209","article-title":"Beta blockers in contemporary cardiology: is it better to cast them out?","volume":"54","author":"Dar","year":"2024","journal-title":"Korean Circ J"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0105","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0106","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF)","volume":"15","author":"Yamamoto","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0107","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102376","article-title":"Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis","volume":"49","author":"Kaddoura","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0108","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jchf.2023.03.017","article-title":"Beta-blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction","volume":"11","author":"Arnold","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0109","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of \u03b2-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0110","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jchf.2023.09.007","article-title":"Contemporary use and implications of beta-blockers in patients with HFmrEF or HFpEF","volume":"12","author":"Peikert","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0111","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cardfail.2021.04.015","article-title":"Association between \u03b2-blockers and outcomes in heart failure with preserved ejection fraction: current insights from the SwedeHF registry","volume":"27","author":"Meyer","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0112","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ejhf.3383","article-title":"Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction","volume":"27","author":"Matsumoto","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0113","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","article-title":"Effect of \u03b2-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction","volume":"78","author":"Palau","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0114","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10741-020-10013-5","article-title":"Effect of beta-blockers on heart failure severity in patients with heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials","volume":"26","author":"Fukuta","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0115","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/CIRCHEARTFAILURE.120.007180","article-title":"Association between \u03b2-blocker use and mortality\/morbidity in patients with heart failure with reduced, midrange, and preserved ejection fraction and advanced chronic kidney disease","volume":"13","author":"Fu","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0116","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cardfail.2023.08.008","article-title":"Does heterogeneity exist in treatment associations with Renin\u2013Angiotensin\u2013System inhibitors or beta-blockers according to phenotype clusters in heart failure with preserved ejection fraction?","volume":"30","author":"Uijl","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0117","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.011694","article-title":"It\u2019s not you, It\u2019s me: uncovering heart-kidney relationship failures","volume":"17","author":"Solomon","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0118","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijcard.2009.09.529","article-title":"Renal function and long-term survival after hospital discharge in heart failure with preserved ejection fraction","volume":"147","author":"Rusinaru","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0119","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0120","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/heartjnl-2022-321404","article-title":"Echocardiographic features of left ventricular dysfunction and outcomes in chronic kidney disease","volume":"109","author":"Ou","year":"2023","journal-title":"Heart"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0121","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1161\/CIRCHEARTFAILURE.123.011173","article-title":"Risk factors and outcomes associated with heart failure with preserved and reduced ejection fraction in people with chronic kidney disease","volume":"17","author":"Bansal","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0122","first-page":"202","article-title":"Treatment of chronic heart failure in advanced chronic kidney disease: the HAKA multicenter retrospective real-world study","author":"Quiroga","year":"2024","journal-title":"Cardiorenal Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0123","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0124","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0125","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0126","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2025.01.022","article-title":"Efficacy of GLP-1 receptor agonists in patients with heart failure and mildly reduced or preserved ejection fraction: a systematic review and meta-analysis","author":"Waqas","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0127","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","article-title":"GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors","volume":"12","author":"Patel","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0129","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.ajkd.2024.11.013","article-title":"Kidney and cardiovascular outcomes among patients with CKD receiving GLP-1 receptor agonists: a systematic review and meta-analysis of randomized trials","volume":"85","author":"Chen","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjcard.2025.10.013_bib0130","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1002\/ejhf.2977","article-title":"Rationale and design of <scp>ENDEAVOR<\/scp> : a sequential phase 2b\u20133 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction","volume":"25","author":"Lund","year":"2023","journal-title":"Eur J Heart Fail"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925006447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925006447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T01:27:11Z","timestamp":1765070831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914925006447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":129,"alternative-id":["S0002914925006447"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.10.013","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heart Failure With Preserved Ejection Fraction and Chronic Kidney Disease: From Pathophysiology to Treatment","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}